Zinc-[gamma]-PGA compositions and methods for treating cancer

• Main Author: Chung, Jinhyuk Fred
• Format: Patent
• Language: English
• Published: 02.04.2024
• Subjects: CHEMISTRY; CIGARETTES; CIGARS; COMPOUNDS THEREOF; DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROMTHE BODY; HUMAN NECESSITIES; HYGIENE; IMPREGNATING OR COATING OF PAPER; INORGANIC CHEMISTRY; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MOUTHPIECES FOR CIGARS OR CIGARETTES; NON-METALLIC ELEMENTS; PAPER NOT OTHERWISE PROVIDED FOR; PAPER-MAKING; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRODUCTION OF CELLULOSE; PULP COMPOSITIONS; SMOKERS' REQUISITES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; TEXTILES; TOBACCO; TOBACCO SMOKE FILTERS; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G

The invention relates to pharmaceutical compositions comprising a zinc2+ salt and a γ-polyglutamic acid carrier, and, optionally, an NF-kB inhibitor as a tumor-sensitizing agent, and methods for using such compositions to treat tumors in patients. Methods include administering a liquid dosage form or a solid dosage form of a therapeutically effective amount of a Zn(II) salt and a γ-polyglutamic acid carrier to a patient in need thereof. Methods of treating a broad spectrum of human tumors, including tumors with a drug-resistant phenotype, using the disclosed compositions are provided. Tumors that respond to the pharmaceutical compositions disclosed herein include neuroendocrine (neuroblastoma), gastric, uterine, and lung tumors.